Looks like some before and some after with no one selling, just buying.
This is what I think the company's strategy is with short Phase 2 and why the big guys are staying in.
If you read the study, seems like there is an immediate strong impact with each dose in the first hour, then tapering down and then slow build up over long periods. The 3 EA patients were at 25 mg for 26 weeks, with incredible transformations. Phase 2A was just one dose. Phase 2b was 12 weeks. Phase 2A and B studies were not designed to test efficiency, but to test dosing and prove safety, which is whats needed to get FDA approval for Phase 3. By not doing a 26 week Phase 2b they cut development time and cost tremendously, a great value for investors who are here for the long game. The company has $25 mil in the bank and hence the immediate SP doesn't impact operations. Saving time though allows them to preserve maximum share holder value long term, if they could get through Phase 3 without major dilution. Just my highly unprofessional observations, would love to hear if others agree.
News 
Market Data 
Discover 
